Global Metastatic Cancer Drug Market – Industry Trends and Forecast to 2029

Market Analysis and Insights

Metastatic cancer (also referred as advanced or stage 4 cancer) occurs when the primary cancer has spread to other parts of the body via the lymphatic or blood circulation systems. Although it can spread to almost every organ in the body, some cancers, such as breast cancer, can spread to the lungs, liver, bones, and brain.

• The metastatic cancer drug is supportive and aims to reduce the severity of the symptoms. Data Bridge Market Research analyses that the metastatic cancer drug market will grow at a CAGR of 7.0% during the forecast period of 2022 to 2029.

Metastatic Cancer Drug Market Dynamics

Drivers

• Growing Cases of Cancer

The rise in the patients suffering from cancer such as breast, lung, melanoma, prostate, and colorectal cancers will result in the expansion of the growth rate of the treatment market.

Moreover, the increase in healthcare expenditure and growing geriatric population are also the growth determinants which bolster the growth of the market. Also, the robust pipeline that leads to potential drugs and availability of treatment options will further enhance the growth of metastatic cancer drug market.

Furthermore, advancement in medical technology, rising government initiatives to spread cancer awareness and growing government funding are the factors that will expand the metastatic cancer drug market. Other factors such as increase in the demand for effective treatment procedures will positively impact the metastatic cancer drug market's growth rate. Additionally, the people of advanced age are more susceptible to the disease and its recurrence will result in the expansion of metastatic cancer drug market. 

Opportunities

Moreover, the rise in the research and development activities and increasing investments by government and private organization will boost new opportunities for the market's growth rate.

Also, the launch of effective therapies and continuous clinical trials will provide beneficial opportunities for the metastatic cancer drug market in the forecast period of 2022-2029. Also, high unmet need of current treatment and developments in healthcare technology will escalate the growth rate metastatic cancer drug market in future.

Restraints/Challenges

However, high cost associated with the associated drugs and lack of infrastructure in low-income countries will impede the growth rate of metastatic cancer drug market. Additionally, the lack of effective treatment for the metastatic disease will hinder the metastatic cancer drug market growth. The serious side effects will further challenge the market in the forecast period mentioned above.

This metastatic cancer drug market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on metastatic cancer drug market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

Metastatic cancer is a cancer that has spread from the primary site to other parts of the body. Metastasis is responsible for 90% of cancer-related deaths, and only a small percentage of patients with metastatic cancer can be treated with traditional methods like chemotherapy, radiotherapy, and surgical removal.

Metastatic cancer drug market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analyzed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

COVID-19 Impact on Metastatic Cancer Drug Market

The sudden emergence of the COVID-19 has negatively affected the market as it prompted the implementation of strict lockdowns and isolation regulations across the globe which complicated the disease management and medication adherence and even further caused delays in the import and export of drugs and medicines. The lack of access to health-care facilities for routine treatment and medication administration due to social distancing regulations will further affect the market.

Recent Developments

• In October 2021, (NASDAQ: ARAY) recently announced that a study published in Frontiers in Oncology found that treating early-stage breast cancer patients with accelerated partial breast irradiation (APBI) delivered using the Accuray CyberKnife ® robotic radiotherapy platform could result in significant improvements in survival. Researchers used complex modelling to find that CyberKnife APBI may have a higher survival rate than other radiation delivery methods like volumetric-modulated arc therapy, three-dimensional conformal radiation therapy ABPI, and high dose rate brachytherapy.
• In October 2020, Lupin launched Lapatinib tablets, which are used to treat metastatic breast cancer. The tablets are 250mg in strength. In the United States, the tablet brought in USD 61 million in sales.

Global Metastatic Cancer Drug Market Scope

The metastatic cancer drug market is segmented on the basis of type, product, treatment, route of administration, dosage, end users and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Prostate Cancer
• Ovarian Cancer
• Colorectal Cancer
• Breast Cancer
• Melanoma
• Lung Cancer
• Others

On the basis of type, the metastatic cancer drug market is segmented into prostate cancer, ovarian cancer, colorectal cancer, breast cancer, melanoma, lung cancer and others.

Product

• Trastuzumab
• Pertuzumab
• Trastuzumab Emtansine

On the basis of product, the metastatic cancer drug market is segmented into trastuzumab, pertuzumab and trastuzumab emtansine.

Treatment 

• Chemotherapy
• Immunotherapy
• Hormonal Therapy
• Surgery
• Others

On the basis of treatment, the metastatic cancer drug market is segmented into chemotherapy, immunotherapy, hormonal therapy, surgery and others.

Route of Administration

• Intravenous
• Intramuscular
• Others

On the basis of route of administration, the metastatic cancer drug market is segmented into intravenous, intramuscular and others.

Dosage

• Injection
• Tablets
• Others

On the basis of dosage, the metastatic cancer drug market is segmented into injection, tablets and others.

End Users

• Hospitals
• Specialty Clinics
• Others

On the basis of end users, the metastatic cancer drug market is segmented into hospitals, specialty clinics and others.

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Others

The metastatic cancer drug market is also segmented on the basis of distribution channel into hospital pharmacy, retail pharmacy and online pharmacy.

Metastatic Cancer Drug Market Regional Analysis/Insights

The metastatic cancer drug market is analysed and market size insights and trends are provided by country, type, product, treatment, route of administration, dosage, end users and distribution channel as referenced above.

The countries covered in the metastatic cancer drug market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the metastatic cancer drug market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period. This is due to high prevalence cases of cancer such as breast and lungs cancer and number of FDA approval drugs in this region.

Asia-Pacific on the other hand is projected to exhibit the highest growth rate during the forecast period due to the focus of various global companies to expand their products in this particular region.

The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Competitive Landscape and Metastatic Cancer Drug Market Share Analysis

The metastatic cancer drug market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to metastatic cancer drug market.

Some of the major players operating in the metastatic cancer drug market are AstraZeneca, Merck & Co., Inc., Pfizer Inc, Celgene Corporation, AKRON, Inc., Novartis AG, Galen Limited, Pacira BioSciences, Inc., Johnson & Johnson Services, Inc, Fresenius Kabi AG, Spectrum Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd, Cipla Inc., Sun Pharmaceutical Industries Ltd., Shanghai Fosun Pharmaceutical(Group) Co., Ltd, and Ingenus among others.

SKU-52135